AstraZeneca PLC (AZN)
| Market Cap | 225.08B |
| Revenue (ttm) | 54.98B |
| Net Income (ttm) | 7.77B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.97 |
| PE Ratio | 14.62 |
| Forward PE | 15.81 |
| Dividend | $1.52 (2.09%) |
| Ex-Dividend Date | Feb 21, 2025 |
| Volume | 6,201,939 |
| Open | 72.65 |
| Previous Close | 73.68 |
| Day's Range | 72.27 - 72.90 |
| 52-Week Range | 61.24 - 87.68 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 95.00 (+30.75%) |
| Earnings Date | Jul 29, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $95.0, which is an increase of 30.75% from the latest price.
News
AstraZeneca's eco-friendly version of smoker's lung inhaler gets EU panel backing
A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.
AstraZeneca's immune disorder drug succeeds in late-stage trial
AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised myasth...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
5 Ideal "Safer" Dividend Buys From Bloomberg's July Watch List
Bloomberg's 50 Companies to Watch leverages catalysts like new leadership, AI, and policy shifts to identify high-potential stocks for 2025. Yield-based 'dogcatcher' analysis spotlights 15 dividend pa...
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to Presi...
AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030
AstraZeneca (AZN) said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about President Donald Trump's tariffs loom over...
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announci...
AstraZeneca commits $50B to US expansion amid Trump tariff pressure
AstraZeneca on Monday announced plans to invest $50 billion in its US operations by 2030, a sweeping commitment that includes building its largest-ever manufacturing facility in Virginia and expanding...
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
AstraZeneca has become the latest pharma firm to announce a multi-billion investment in the U.S. The Anglo-Swedish biotech firm has committed to spend $50 billion by 2030.
AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats
UK company to fund new drug manufacturing facility in Virginia and expand R&D facilities around US
AstraZeneca to invest $50B in US economy by 2030
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This ...
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to Presi...
AstraZeneca drug fails main goal of late-stage amyloidosis study
AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of pro...
AstraZeneca shares show signs of life after successful trials of hypertension drug
Baxdostat trials showed immense promise for huge available market.
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically mean...
AstraZeneca drug lowers high BP in late-stage study; shares rise
AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugmake...
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
AstraZeneca: Just What The Doctor Ordered
AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds...
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus...
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports
Summit Therapeutics is considering an up to $15 billion partnership with AstraZeneca , Bloomberg News reported on Thursday, citing people familiar with the matter.
AstraZeneca exit: here's what it really means for the UK
AstraZeneca Plc (LON: AZN) is in focus this morning following reports that its chief executive – Pascal Soriot is considering moving the giant's listing to the US.
AstraZeneca boss ‘wants to shift stock market listing to US'
Report claims CEO Pascal Soriot talked in private about moving UK's most valuable listed company and considered shifting its domicile
AstraZeneca CEO eyes US market listing, The Times reports
AstraZeneca chief executive Pascal Soriot is considering moving the company's stock market listing to the United States, The Times reported on Tuesday, citing multiple sources.